Ballicules.com

Trihexyphenidyl

ARTANE

What it isCentral antimuscarinic; drug-induced parkinsonism, dystonia and tremor.

Why this oneIt is effective for dystonia, including the primary dystonias, where few oral agents work.

What limits itAnticholinergic burden and cognitive impairment, so it is poor in the elderly. It does not help tardive dyskinesia and can worsen it.

FDA-approved for

Off-label

FDA label

FDA dosingPopulationStartTargetMax
Idiopathic parkinsonismAdults1 mg on day 16–10 mg/day12–15 mg/day (postencephalitic)
Drug-induced extrapyramidal reactionsAdults1 mg5–15 mg/day15 mg/day

Titration Increase by 2 mg increments every 3 to 5 days (parkinsonism)

Renal Undefined

Hepatic Undefined

Instructions

Cautions

Adverse reactions

Pregnancy Undefined

Lactation Undefined

NO BOXED WARNINGS

Principal riskAnticholinergic burden and cognitive impairment

Cost, est. cash$5–$150/month

Generic entry1982

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability1 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism4 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryC

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Mechanism of action: Trihexyphenidyl ballicule

Trihexyphenidyl ballicule: receptor binding, kinetics and half-life diagram

Open Trihexyphenidyl in the interactive console ↗

Memory aids: mascots and interaction avatars

Trihexyphenidyl ARTANE mascot mnemonic cartoon
“Triangle-hexagon Art thing”
“mad as a hatter” → BBB-crossing antimuscarinic
Trihexyphenidyl Box: minimal PK interactions avatar
Box: minimal PK interactions

Open Trihexyphenidyl in the interactive console ↗